# AstraZeneca

Source: https://nuclide.cc/companies/astrazeneca/  
Nuclide record `astrazeneca` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.

## Summary

AstraZeneca's oncology revenue exceeds $20B. ADCs (T-DXd, Dato-DXd with Daiichi Sankyo; AZD0901 CLDN18.2; puxitatug samrotecan B7-H4; tilatamig samrotecan EGFR×MET bsADC), osimertinib, olaparib, capivasertib, durvalumab, camizestrant, saruparib, and radioconjugates via Fusion Pharma (225Ac-PSMA). Also cell therapy (Neogene, GPC3 CAR-T).

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Acerta Pharma; Alexion Pharmaceuticals; MedImmune LLC; MedImmune
- HQ: Cambridge
- Type: pharma
- Website: https://www.astrazeneca.com
- Ticker: AZN

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/AstraZeneca
- Official website: https://www.astrazeneca.com

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/)
- drugs: [Actinium-225 FPI-2068](https://nuclide.cc/drugs/ac-225-fpi-2068/), [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [Durvalumab](https://nuclide.cc/drugs/durvalumab/), [FPI-2265](https://nuclide.cc/drugs/fpi-2265/), [Olaparib](https://nuclide.cc/drugs/olaparib/)
- trials: [A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat](https://nuclide.cc/trials/nct06040099/), [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://nuclide.cc/trials/alphabreak/), [AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)](https://nuclide.cc/trials/nct07611110/), [FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct06909825/), [Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer](https://nuclide.cc/trials/nct07590934/), [Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).](https://nuclide.cc/trials/nct05219500/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [HER2-positive breast cancer](https://nuclide.cc/indications/breast-her2-positive/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/), [Thyroid cancer](https://nuclide.cc/indications/thyroid/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://nuclide.cc/technologies/actinium-225-supply/)
- pairings: [Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/)

---
JSON: https://nuclide.cc/api/v1/entities/astrazeneca.json